Gene therapy promises to become a durable clinical option for a whole range of diseases, including monogenic hereditary diseases, cancer and neurodegenerative disorders. However, the development of new gene therapy-based treatment...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ONCOmetENHANCERS
Elucidating the Role of Enhancer Methylation Variation in Ca...
2M€
Cerrado
PID2019-108082GA-I00
BIOLOGIA SINTETICA DE ELEMENTOS REGULADORES DE GENES MEDIANT...
157K€
Cerrado
DUALgRENP
A DUAL gRNA system for functional assessment of ENhancers in...
183K€
Cerrado
ENHPATHY
Molecular basis of human enhanceropathies
4M€
Cerrado
TimedEnhancer
Temporal dependence of enhancer function
2M€
Cerrado
AML-SynergyX
Systematic identification of genetic modifiers in the respon...
186K€
Cerrado
Información proyecto EnhancerDesign
Duración del proyecto: 19 meses
Fecha Inicio: 2020-11-19
Fecha Fin: 2022-06-30
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Gene therapy promises to become a durable clinical option for a whole range of diseases, including monogenic hereditary diseases, cancer and neurodegenerative disorders. However, the development of new gene therapy-based treatments strongly depends on regulatory drivers that provide cell-type specific expression of the transgene, at high enough levels, yet without causing genotoxicity.
The aim of the ERC PoC proposal is to validate a state-of-the-art pipeline, called EnhancerDesign, to design small, strong and cell-type specific human enhancers for gene therapy that will improve specificity and safety, the two major bottlenecks in gene therapy applications. The strength of our EnhancerDesign approach lies in understanding and exploiting the enhancer code by using several state-of-the-art bioinformatics and experimental techniques. We have designed and now aim to validate our pipeline consisting of four parts (1) Single-cell multi-omics profiling; (2) training enhancer models to gain understanding of the enhancer logic; (3) design synthetic sequences in silico; (4) high-throughput enhancer testing.
The project outcome will be twofold. Firstly, the different modules in our pipeline will be further optimized to make the entire pipeline operational to be offered as a service to, or as an asset for collaborative projects with gene therapy companies. Secondly, this project will deliver novel enhancers for a set of chosen cell types, for which no specific enhancers exist, or for which the available enhancers are either too large, too unspecific, or too weak.
Altogether, the development of optimized enhancers by our EnhancerDesign pipeline will allow for improved and cell-type specific expression of a transgene, and has therefore the potential to provide patients with a safer treatment, increased QoL and new treatment options for diseases where gene therapy was not yet an option.